Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorKATO, Ken
dc.contributor.authorAJANI, Jaffer A.
dc.contributor.authorDOKI, Yuichiro
dc.contributor.authorXU, Jianming
dc.contributor.authorWYRWICZ, Lucjan
dc.contributor.authorMOTOYAMA, Satoru
dc.contributor.authorOGATA, Takashi
dc.contributor.authorKAWAKAMI, Hisato
dc.contributor.authorHSU, Chih-Hung
dc.contributor.authorADENIS, Antoine
dc.contributor.authorHAJBI, Farid El
dc.contributor.authorBARTOLOMEO, Maria Di
dc.contributor.authorBRAGHIROLI, Maria Ignez Freitas Melro
dc.contributor.authorHOLTVED, Eva
dc.contributor.authorMURPHY, Mariela A. Blum
dc.contributor.authorPATEL, Apurva
dc.contributor.authorHU, Nan
dc.contributor.authorMATSUMURA, Yasuhiro
dc.contributor.authorCHAU, Ian
dc.contributor.authorKITAGAWA, Yuko
dc.date.accessioned2024-03-08T15:15:00Z
dc.date.available2024-03-08T15:15:00Z
dc.date.issued2023
dc.description.conferencedateJAN 19-21, 2023
dc.description.conferencelocalSan Francisco, CA
dc.description.conferencenameGenitourinary Cancers Symposium
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.sponsorshipBristol Myers Squibb
dc.identifier.citationJOURNAL OF CLINICAL ONCOLOGY, v.41, suppl.4, p.290-290, 2023
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58518
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofJournal of Clinical Oncology
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.subject.wosOncologyeng
dc.titleNivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.eng
dc.typeconferenceObjecteng
dc.type.categorymeeting abstracteng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.contributor.author-fmusphcMARIA IGNEZ FREITAS MELRO BRAGHIROLI
hcfmusp.description.beginpage290
hcfmusp.description.endpage290
hcfmusp.description.issuesuppl 4
hcfmusp.description.volume41
hcfmusp.origemWOS
hcfmusp.origem.wosWOS:001093994600367
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
relation.isAuthorOfPublicatione8f6ecfd-384c-4cd9-a8ef-c27fc574321a
relation.isAuthorOfPublication.latestForDiscoverye8f6ecfd-384c-4cd9-a8ef-c27fc574321a
Arquivos
Coleções
Comunicações em Eventos - HC/ICESP
Comunicações em Eventos - LIM/24